InsidersTradesSigma
Browse the detailed record of transactions filed by Bent Frandsen, 首席执行官. Officer active across 2 companies, notably Expres2ion Biotech Holding AB. Cumulatively, 2 disclosures have been published. History available since 20 April 2026. The latest transaction was disclosed on 1 May 2026 (Purchase). Regulator: FIN-FSA. All data is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 条申报中的 2 条
Bent Frandsen is the Chief Executive Officer of Expres2ion Biotech Holding AB. He is responsible for the daily management of the company and the implementation of its strategy. His leadership is essential for the development and growth of the company in the biotechnology sector.